Skip to content
Open access

Comparison of Prediction Formulas for CPAP Titration in Patients with Sleep Apnoea Syndrome

Aug 2026 · Muğla Sıtkı Koçman Üniversitesi tıp dergisi · Vol 13, pp. 214-220 · 0 citations · 10 references

TL;DR

The Loredo formula demonstrated superior accuracy in predicting CPAP titration pressures, suggesting that it may be a reliable alternative to manual titration methods in clinical practice.

Abstract

Continuous Positive Airway Pressure (CPAP) therapy has revolutionized the treatment of Obstructive Sleep Apnea Syndrome (OSAS), first reported in 1981. Manual CPAP titration can lead to a number of constraints and loss of time and labor for the patient and relatives, the healthcare worker, and the healthcare system. Therefore, the use of predictive forecasting formulas has a positive benefit. This study aims to compare the effectiveness of three widely used prediction formulas—Hoffstein, Loredo et al., and Hukins—against manually titrated CPAP pressure values in patients diagnosed with OSAS. The study included 69 patients first diagnosed with OSAS in our center's polysomnography (PSG) laboratory between 2010 and 2024 and underwent CPAP titration during a whole-night sleep study. Three predictive formulas were compared, and their agreement with manual titration was evaluated. The comparison of predicted pressures revealed that the Loredo formula provided the closest estimates to manual titration pressures, showing the least systematic difference (-0.07101) and absolute percentage error (11.11%). In contrast, the Hoffstein formula exhibited the highest systematic difference (-2.4174), while the Hukins formula had moderate predictive validity. Overall, the Loredo formula demonstrated superior accuracy in predicting CPAP titration pressures, suggesting that it may be a reliable alternative to manual titration methods in clinical practice. Future research should focus on validating these formulas across larger and more diverse populations to enhance their applicability in routine clinical settings.

Read PDF

Similar papers

Sep 2026

Ventilatory burden and blood pressure response to CPAP: A secondary analysis of the APPLES trial.

BACKGROUND Continuous Positive Airway Pressure (CPAP) is the standard treatment of obstructive sleep apnea (OSA), but has a heterogeneous blood pressure (BP) lowering effect. We hypothesized that Ventilatory Burden (VB), a metric better reflecting the entire burden of pathological airflow, may predict CPAP-induced BP r...

Wen-Tao Wu, Li-Mei Mao, A. Parekh et al. · 0 citations
Open access Sep 2026

Association of Obstructive Sleep Apnoea Severity with Nocturnal Blood Pressure and Autonomic Dysfunction in Patients with Hypertension.

ABPM with OSA screening may help identify high-risk nocturnal blood pressure phenotypes in hypertensive patients and greater OSA severity was associated with higher nocturnal SBP and possible autonomic imbalance.

Hui Sun, Le Xie, Lu Gan et al. · 0 citations
Open access Sep 2026

Sense of Coherence and Its Association With Adherence to Continuous Positive Airway Pressure (CPAP) Therapy in Patients With Obstructive Sleep Apnoea

It is suggested that low SOC is a risk factor for non-adherence to treatment and is a key clinical predictor for developing motivational strategies to improve treatment persistence in patients with OSA.

Monserrat Gómez Juárez, Fátima K. Gaytán Núñez, Francisco Vargas Hernández et al. · 0 citations
Open access Sep 2026

Role of drug induced sleep endoscopy in morphological diagnosis with continuous positive airway pressure titration in OSA patients

Continuous positive airway pressure (CPAP) is the most extremely effective treatment for moderate-to-severe OSA. Though, upper airway (UAW) obstruction location identification is a difficult task in order to comprehend the potential mechanism of a high CPAP titration level, which can be achieved through DISE-assisted C...

Ola Abd-ELAzize Romeh, Mostafa Ammar, R. Sharshar et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.